Solventum Co. (NYSE:SOLV) Position Boosted by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Solventum Co. (NYSE:SOLV) by 2.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 13,677 shares of the company’s stock after buying an additional 264 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Solventum were worth $904,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Modus Advisors LLC acquired a new position in shares of Solventum in the 4th quarter worth approximately $25,000. Copeland Capital Management LLC bought a new position in Solventum during the third quarter worth $26,000. Mather Group LLC. acquired a new position in Solventum in the third quarter worth $27,000. Crews Bank & Trust bought a new stake in Solventum during the fourth quarter valued at $32,000. Finally, True Wealth Design LLC raised its holdings in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the period.

Solventum Stock Performance

SOLV opened at $73.57 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The business’s 50 day moving average is $70.45 and its 200-day moving average is $68.20. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.

Analyst Ratings Changes

Several research analysts have recently commented on SOLV shares. Morgan Stanley lifted their price target on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Mizuho assumed coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price for the company. Finally, Piper Sandler increased their price target on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.